16 results about "Glycoprotein binding" patented technology

The invention relates to the technical field of biology, in particular to a multivalent pneumococcal polysaccharide-protein conjugate immunogenic composition for preventing pneumococcal and varicella-zoster virus infection as well as a preparation method and application of the multivalent pneumococcal polysaccharide-protein conjugate immunogenic composition. The immunogenic composition of the present invention comprises: at least one pneumococcal polysaccharide-protein conjugate wherein the pneumococcal polysaccharide is linked to a carrier protein through a covalent bond; the carrier protein is varicella-zoster virus glycoprotein E, namely VZV gE recombinant protein, and the amino acid sequence of the VZV gE recombinant protein is shown as SEQ ID NO: 3 or SEQ ID NO: 4. The immunogenic composition containing the multivalent pneumococcal polysaccharide-protein conjugate, provided by the invention, shows a remarkable synergistic interaction effect, and realizes a'dual enhancement 'effect.

The present disclosure provides antibodies and antigen-binding fragments that are capable of binding to RSV and / or MPV fusion glycoproteins and that are capable of neutralizing RSV and / or MPV infection. Also provided are polynucleotides encoding the antibodies, vectors comprising such polynucleotides, host cells capable of expressing these antibodies, related compositions, and methods of using the compositions disclosed herein, for example, to treat or prevent RSV and / or MPV infection.

The present invention describes a (first) anti-HSV antibody or antigen-binding fragment thereof that binds to glycoprotein B (gB) of HSV-1 and / or HSV-2 wherein the antibody comprises complementarity determining regions VHCDR1, VHCDR3, VLCDR1, VLCDR2 and VLCDR3, each comprising a sequence defined in the claims wherein the antibody or antigen-binding fragment has a sequence of at most 5.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 5.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 a low dissociation rate kdis of up to 5.0 x 10 <-5 > s <-1 > and most preferably up to 2.9 x 10 <-5 > s <-1 >. In addition, the present invention also describes a combination of (A) the (first) anti-HSV antibody or antigen-binding fragment thereof; and (B) a second anti-HSV antibody or antigen-binding fragment thereof that recognizes / binds to glycoprotein B (gB) of HSV-1 and / or HSV-2 wherein the antibody comprises complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3, each comprising the sequences defined in the claims wherein the second antibody has a dissociation constant Kd of at most 40 nM, preferably at most 30 nM, more preferably at most 20 nM, even more preferably at most 15 nM, at most 13 nM and at most 10 nM. Furthermore, the present invention also describes a pharmaceutical composition comprising an effective amount of said anti-HSV antibody or antigen-binding fragment thereof, or a combination of said antibodies, and at least one pharmaceutically acceptable excipient. Furthermore, the present invention also describes an anti-HSV antibody or antigen binding fragment thereof or said combination of said antibodies for use in a method of prophylactic or therapeutic treatment of a disorder or disease as defined in the claims. Furthermore, the present invention also describes a bispecific antibody that binds to glycoprotein B (gB) of HSV-1 and / or HSV-2, comprising: (A) a first binding domain comprising: complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3 of the aforementioned first antibody; and (B) a second binding domain comprising: complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 of the aforementioned second antibody; wherein the bispecific antibody has a low dissociation rate kdis of at most 5.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, at most 5.0 x 10 <-5 > s <-1 >, most preferably at most 2.9 x 10 <-5 > s <-1 >. Finally, the present invention describes a trispecific antibody comprising a third binding domain in addition to the first binding domain and the second binding domain as described for the bispecific antibody.

Provided are a pneumococcal conjugate combined vaccine and a preparation method therefor. The combination comprises 26 different pneumococcal polysaccharide-protein conjugates, and the pneumococcal polysaccharide comprises a total of 26 serotypes, i.e., 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 24F, 33F and 35B. The carrier protein used by the conjugate is tetanus toxoid (TT). The polysaccharide is covalently linked to the TT by means of a cyano activation method so as to prepare a polysaccharide-protein conjugate stock solution, and the polysaccharide-protein conjugate stock solution is then adsorbed by an aluminum adjuvant in an appropriate proportion so as to obtain the pneumococcal conjugate vaccine. The pneumococcal polysaccharide used therein requires no degradation reaction, effectively protecting the antigenicity of the polysaccharide. Three consecutive batches of production of the conjugate stock solution and vaccine are performed, and the yield and each verification index of the conjugate are stable. The results of non-clinical safety evaluation research show that the vaccine has good safety and immunogenicity. The prepared pneumococcal conjugate vaccine is used for immunoprophylaxis of pneumococcal infection of relevant serotypes.

The invention provides construction of a universal influenza virus fluorescent molecular imprinting sensor and a method for visually detecting influenza viruses. In the invention, a zeolite imidazolate skeleton (ZIF-8) coated red fluorescent quantum dots (R-QDs) is used as an imprinting carrier and signal output, influenza virus H7N9 is used as a template, and the molecularly imprinted polymer (MIPs) is prepared by a sol-gel technology. Meanwhile, the surfaces of the magnetic Fe3O4 nanoparticles are modified with phenylboronic acid (Fe3O4-FPBA) to serve as a capture element, and when the H7N9 virus is specifically bound with the MIPs, Fe3O4-FPBA can be bound with glycoprotein on the surface of the virus through boric acid esterification reaction, so that a sandwich composite structure of MIPs-virus-Fe3O4-FPBA is formed. Through the formation of the structure, separation and enrichment of a target object can be realized through a magnet, and meanwhile, the change of a quantum dot fluorescence signal is caused, so that visual detection of a target virus is realized, and high-sensitivity quantitative detection can also be performed through an ultraviolet and visible spectrophotometer. The sensor prepared by the invention is a general influenza virus sensor, and the fluorescent sensor suitable for visually detecting other target objects can be prepared by selecting other subtype influenza viruses as template molecules for molecular imprinting.